Navigation Links
Study reveals how fusion protein triggers cancer
Date:1/27/2011

ANN ARBOR, Mich. What happens when two proteins join together? In this case, they become like a power couple, where the whole is greater than the sum of the parts.

API2 and MALT1 are two proteins that become fused together in a subset of lymphomas. The API2 part of the fusion connects with an enzyme called NIK. When it does, MALT1 comes in for the kill, splitting NIK in two, a process called cleavage.

The result? NIK is stronger than ever. It sheds its "conscience" by removing a regulatory region of the enzyme that forces NIK to behave and self-destruct. Consequently, NIK acts like a renegade protein, making cancer cells that grow, spread and resist traditional treatments.

This is the picture researchers at the University of Michigan Comprehensive Cancer Center uncovered in a study publishing in the Jan. 28 issue of Science. Led by a husband and wife team, Linda McAllister-Lucas, M.D., Ph.D., and Peter C. Lucas, M.D., Ph.D., U-M researchers coordinated an international effort that included contributions from laboratories in Great Britain and Belgium.

The API2-MALT1 fusion protein appears 30 percent to 40 percent of the time in a type of B-cell lymphoma called mucosa-associated lymphoid tissue, or MALT, lymphoma. It's never seen in any other cells.

"NIK is a critical hub that's been implicated in other B-cell cancers. Cleavage of NIK by this fusion oncoprotein suggests a new way of activating NIK, and further supports that NIK represents a potential target for developing new therapies," says McAllister-Lucas, associate professor of pediatric hematology/oncology at the U-M Medical School.

The protein fusion itself is also a potential treatment target. Neither API2 nor MALT1 alone can cause a ripple effect on NIK. It happens only when the two fuse together, with API2 providing the access for MALT1 to cause the split. Without the fusion, NIK cleavage does not happen.

"A particularly exciting feature to this discovery is that the critical cancer-causing event involves a kinase -- NIK -- and a protease -- API2-MALT1. Both kinases and proteases are considered druggable, meaning they are potential targets for developing drugs that block their activity," says Lucas, assistant professor of pathology at the U-M Medical School.

MALT lymphomas that carry the API2-MALT1 fusion protein tend to be more aggressive and more resistant to treatment. The result is larger tumors and increased spread throughout the body.

The researchers found that once NIK becomes stable, it triggers a series of downstream reactions that make cells more likely to metastasize and more resistant to current treatments.

These effects were reversed when researchers turned off NIK, suggesting that either blocking NIK or preventing NIK from becoming stable by blocking the protein fusion, could halt the growth and spread of MALT lymphoma tumors.

While NIK inhibitors are being investigated, these therapies are not currently available.


'/>"/>

Contact: Nicole Fawcett
nfawcett@yahoo.com
734-764-2220
University of Michigan Health System
Source:Eurekalert  

Related medicine news :

1. Study finds MRSA screening saves hospitals money
2. New national study finds 34 percent increase in running-related injuries among children
3. Study Ties Hot Flashes to Lower Breast Cancer Risk
4. Yearly mammograms from age 40 save 71 percent more lives, study shows
5. Organic food in pregnancy -- new study
6. Abortion Typically Doesnt Harm Mental Health: Study
7. Widespread Use of Defibrillators in Public Places Saves Lives: Study
8. RIC study suggests researchers are entering a new era of advances in brain research
9. Sharing child caregiving may increase parental conflict, study finds
10. Stroke Centers Providing Better Care, Study Finds
11. Study raises safety concerns about experimental cancer approach
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Study reveals how fusion protein triggers cancer
(Date:8/18/2017)... ... August 18, 2017 , ... ... services to communities in east Texas, is launching a regional charity effort to ... Founded in 1991, the Pediatric Brain Tumor Foundation (PBTF) has raised nearly $30 ...
(Date:8/18/2017)... Bedford, TX (PRWEB) , ... August 18, 2017 , ... ... serves communities in the Dallas/Fort Worth area, is spearheading a regional charity campaign organized ... her husband. , In early June of this year, Christina and her children returned ...
(Date:8/18/2017)... ... 2017 , ... Alcovit, a lime-flavored beverage that rids the body of toxins ... product now available through Jet.com. , After 25 years of development, the company ... designed to quickly detox the body thereby avoiding alcohol-induced hangovers. Whether you’re having fun ...
(Date:8/18/2017)... , ... August 18, 2017 , ... “Dangerous Inheritance”: a ... author, Diane Winters. Diane is from Southwest Nebraska where she was raised on ... and family. The story is fictional, but the friendships and mantra of ‘neighbors ...
(Date:8/18/2017)... ... August 18, 2017 , ... Rollon Skin ... anti-aging skincare solutions, recently announced the launch of two new skincare products, ... yet effective alternative to expensive plastic surgery or in-patient cosmetic dermatological procedures. , ...
Breaking Medicine News(10 mins):
(Date:8/4/2017)... -- Agragen, LLC, a Cincinnati -based ... and aquacultural feed sectors, announces a significant step ... AGR131.  This drug is designed to trap and ... patients suffering from inflammatory conditions such as rheumatoid ... Biological pharmaceuticals currently used ...
(Date:8/2/2017)...   Marshall County Hospital in Benton, Kentucky has added ... hospital-acquired infections (HAIs). The new addition, Tru-D SmartUVC , short for "total room ultraviolet ... such as C. diff , MRSA, MERS, Ebola and more. ... Tru-D SmartUVC ... Tru-D in action in a patient room ...
(Date:8/1/2017)...   CerSci Therapeutics , a non-opioid drug development ... has received notice from the National Institute on Drug ... that it has been awarded a Direct-to-Phase II Small ... 2017 with an additional $1,000,000 to follow in 2018. ... of their lead non-opioid drug candidate CT-044 to the ...
Breaking Medicine Technology: